Ban T A, Wilson W H, McEvoy J P
Int Pharmacopsychiatry. 1980;15(3):166-70. doi: 10.1159/000468433.
Amoxapine, a new antidepressant, is a tricyclic debenzoxazepine compound, the demethylated metabolite of the neuroleptic loxapine. In animal pharmacological studies, amoxapine has shown striking similarities to imipramine. In contrast to the prototype antidepressant drug, however, amoxapine does not interact with serotonin. In 10 uncontrolled clinical trials amoxapine was shown to have antidepressant effects in the dosage range of 100-300 mg/day. This was verified in 10 published standard, and placebo and standard controlled clinical studies in which amoxapine was superior to placebo and equal in overall therapeutic efficacy to imipramine and amitriptyline. Side effects were similar to the reference drugs.
阿莫沙平是一种新型抗抑郁药，是一种三环二苯并恶嗪化合物，为抗精神病药洛沙平的去甲基代谢产物。在动物药理学研究中，阿莫沙平已显示出与丙咪嗪有显著相似性。然而，与原型抗抑郁药不同的是，阿莫沙平不与血清素相互作用。在10项非对照临床试验中，阿莫沙平在100 - 300毫克/天的剂量范围内显示出抗抑郁作用。这在10项已发表的标准、安慰剂和标准对照临床研究中得到了验证，其中阿莫沙平优于安慰剂，总体治疗效果与丙咪嗪和阿米替林相当。副作用与对照药物相似。
